Concenter BioPharma/Silkim Ltd.

Developing Novel Drugs for TYPE 2 DIABETES, IBD and PSORIASIS based on a Core-Technology-Platform, Utilizing the 505(b)(2) Pathway (IND Phase)

  • Stage Product In Development
  • Industry Biotechnology
  • Location Jerusalem, Israel
  • Currency USD
  • Founded January 2014
  • Employees 6
  • Incorporation Type Other
  • Website concenterbiopharma.com

Company Summary

Pipeline (IND's in process):
o T2D drug - demonstrated as effective in both prevention and treatment of T2D.
o Psoriasis drug - demonstrated efficient treatment of psoriasis, dermatitis, wound healing, burns.
o Inflammatory Bowel Diseases (IBD) drug - demonstrated efficient treatment for both Crohn's Disease and Ulcerative Colitis.

Raising $ for Clinical Trials (Phase 2) and IP enhancement (14 months)

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free